Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014 e1.

Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841–50.

Article  PubMed  PubMed Central  Google Scholar 

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52.

Article  PubMed  Google Scholar 

•• Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. This comprehensive guideline statement defines new criteria for the definition and diagnosis of MAFLD. The unifying of consensus on the criteria will enhance the clinical treatment of MALFD.

Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–61.

Article  PubMed  Google Scholar 

Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, et al. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020;10(1):21117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215. This is a very comprehensive review discussing the strong association between NAFLD and the risk of cardiovascular disease (CVD). It also gives useful guidelines for the treatment of CVD in NAFLD patients.

DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. Diabetol Metab Syndr. 2022;14(1):45.

Article  PubMed  PubMed Central  Google Scholar 

• Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329–41. This is an excellent review of NAFLD in lean individuals.

Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65–72.

Article  PubMed  PubMed Central  Google Scholar 

Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290–9.

Article  CAS  PubMed  Google Scholar 

Saxton SN, Clark BJ, Withers SB, Eringa EC, Heagerty AM. Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue. Physiol Rev. 2019;99(4):1701–63.

Article  CAS  PubMed  Google Scholar 

•• Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010. This is the most recent scientific statement from the American Heart Association on obesity and the risk for the development of cardiovascular disease.

von Jeinsen B, Vasan RS, McManus DD, Mitchell GF, Cheng S, Xanthakis V. Joint influences of obesity, diabetes, and hypertension on indices of ventricular remodeling: findings from the community-based Framingham Heart Study. PLoS ONE. 2020;15(12):e0243199.

Article  Google Scholar 

Dornas W, Schuppan D. Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020;319(3):G400–11.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

Article  PubMed  Google Scholar 

Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology. 2013;154(9):3099–109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58(1):250–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149(12):6018–27.

Article  CAS  PubMed  Google Scholar 

Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456–63.

Article  CAS  PubMed  Google Scholar 

Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J, et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice. Cell Metab. 2018;27(6):1323–37 e5.

Weng HC, Lu XY, Xu YP, Wang YH, Wang D, Feng YL, et al. Fibroblast growth factor 21 attenuates salt-sensitive hypertension-induced nephropathy through anti-inflammation and anti-oxidation mechanism. Mol Med. 2021;27(1):147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19–31.

Article  CAS  PubMed  Google Scholar 

Tanajak P, Sa-Nguanmoo P, Wang X, Liang G, Li X, Jiang C, et al. Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats. Acta Physiol (Oxf). 2016;217(4):287–99.

Article  CAS  PubMed  Google Scholar 

Sommakia S, Almaw NH, Lee SH, Ramadurai DKA, Taleb I, Kyriakopoulos CP, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910.

Article  CAS  PubMed  Google Scholar 

Pandhi P, Ter Maaten JM, Anker SD, Ng LL, Metra M, Samani NJ, et al. Pathophysiologic processes and novel biomarkers associated with congestion in heart failure. JACC Heart Fail. 2022;10(9):623–32.

Article  PubMed  Google Scholar 

von Loeffelholz C, Horn P, Birkenfeld AL, Claus RA, Metzing BU, Docke S, et al. Fetuin A is a predictor of liver fat in preoperative patients with nonalcoholic fatty liver disease. J Invest Surg. 2016;29(5):266–74.

Article  Google Scholar 

Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab. 2012;97(12):4717–23.

Article  CAS  PubMed  Google Scholar 

Laughlin GA, Cummins KM, Wassel CL, Daniels LB, Ix JH. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012;59(19):1688–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kocyigit I, Unal A, Elcik D, Korkar H, Sen A, Yasan M, et al. Association between cardiac valvular calcification and serum fetuin-A levels in renal transplant recipients. Transplant Proc. 2015;47(5):1398–401.

Article  CAS  PubMed  Google Scholar 

Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021;144(23):e472–e87. This is the most recent scientific statement from the American Heart Association on evidence-based dietary pattern guidelines to promote cardiometabolic health.

Wei S, Binbin L, Yuan W, Zhong Z, Donghai L, Caihua H. Beta-hydroxybutyrate in cardiovascular diseases: a minor metabolite of great expectations. Front Mol Biosci. 2022;9:823602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019;4(4).

Mey JT, Erickson ML, Axelrod CL, King WT, Flask CA, McCullough AJ, et al. Beta-hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro. Am J Physiol Endocrinol Metab. 2020;319(1):E187–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fletcher JA, Deja S, Satapati S, Fu X, Burgess SC, Browning JD. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCI Insight. 2019;5(11).

Chakraborty S, Galla S, Cheng X, Yeo JY, Mell B, Singh V, et al. Salt-responsive metabolite, beta-hydroxybutyrate, attenuates hypertension. Cell Rep. 2018;25(3):677–89 e4.

McCarthy CG, Waigi EW, Yeoh BS, Mell B, Vijay-Kumar M, Wenceslau CF, et al. Low-dose 1,3-butanediol reverses age-associated vascular dysfunction independent of ketone body beta-hydroxybutyrate. Am J Physiol Heart Circ Physiol. 2022;322(3):H466–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flores-Guerrero JL, Westenbrink BD, Connelly MA, Otvos JD, Groothof D, Shalaurova I, et al. Association of beta-hydroxybutyrate with development of heart failure: sex differences in a Dutch population cohort. Eur J Clin Invest. 2021;51(5):e13468.

Article  CAS  PubMed  Google Scholar 

Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75(2):275–84.

Article  CAS  PubMed  Google Scholar 

Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285(23):17271–6.

Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L, et al. Metabolic dysfunction-associated fatty liver disease (MAFLD)-a condition associated with heightened sympathetic activation. Int J Mol Sci. 2021;22(8).

Kakouri N, Andrikou I, Konstantinidis D, Siafi E, Kariori M, Drogkaris S, et al. Sympathetic nervous system activity and blood pressure in hypertensive patients with nonalcoholic fatty liver disease. J Hypertens. 2022;40(Suppl 1):e124.

Article  Google Scholar 

Geerling JJ, Boon MR, Kooijman S, Parlevliet ET, Havekes LM, Romijn JA, et al. Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies. J Lipid Res. 2014;55(2):180–9.

留言 (0)

沒有登入
gif